Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Technology
January 29, 2015 12:00 AM

Tamiflu controversy reignited by new study

Sabriya Rice
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    The antiviral medication Tamiflu shortened the length of time patients experienced flu symptoms, and reduced rates of complications and hospitalizations from the virus, a new study finds. But it did not have an effect on those with flu-like symptoms who did not have the flu.

    The findings already are being challenged by some because they conflict with those of another report almost a year ago that raised serious questions about the drug's safety and efficacy. That report claimed the harms are understated and called government stockpiles of the antivirals a waste of money. Critics are latching on to the involvement of drugmaker Roche in the new study as evidence its findings are questionable even though authors say Roche had no active role in the new report.

    “That's the conclusion I would have expected from a Roche-sponsored reanalysis,” said Dr. Peter Doshi, assistant professor of pharmaceutical health services research at the University of Maryland. Doshi was part of a team to review a Cochrane study published last year in The BMJ, which questioned government stockpiling of antiviral flu medications.

    The new report comes as the U.S. is in the throes of what health officials warn could be a severe flu season. The proportion of people reporting flu-like illness has remained above the national baseline for the ninth consecutive week, according to estimates from the Centers for Disease Control. Earlier this month, CDC director Dr. Tom Frieden recommended early, aggressive treatment with antivirals in patients suspected of having the flu virus, even if the virus is not confirmed.

    “It's is not a perfect antiviral, but it should be a component of treatment,” said Dr. Arnold Monto, an epidemiology professor at the University of Michigan, one of the authors of a new study designed to clear up the debate about the efficacy of oseltamivir (Tamiflu) treatment. “There are few side effects so the risk-benefit is better” than using antibiotics. "Our findings confirm Tamiflu's role,” he said.

    Monto and a team of researchers obtained published and unpublished Roche-sponsored randomized, placebo-controlled, double-blind trials on the drug for the meta-analysis, which included nine trials conducted between 1997 and 2001 and a total of 4,328 patients. Patients had been given either 75 mg doses of oseltamivir or a placebo, within 36 hours of feeling sick, and continued the drug regimen for five days at 12-hour intervals.

    The analysis found that among patients infected with the flu virus, symptoms like aches, sore throat, nasal congestion and chills, cleared up in about four days, while it took an extra day for placebo patients. They also had fewer lower respiratory complications—like pneumonia or bronchitis—requiring antibiotics more than 48 hours later, and were less likely to be hospitalized. Although side effects like nausea, vomiting and gastrointestinal disorders were more prevalent, there was no evidence of serious adverse events, like neurological or psychiatric disorders.

    The findings from Monto, Joanna Dobson and Stuart Pocock of the London School of Hygiene & Tropical Medicine and Dr. Richard Whitley of the University of Alabama at Birmingham, were published Thursday in the journal The Lancet.

    The Cochrane review used some of the same data obtained by the Lancet researchers, but found no evidence that the drug reduced pneumonia complications, led to fewer hospitalizations or stopped the spread of a pandemic. It also said worrisome side effects—like the potential for psychiatric and renal problems and hypoglycemia—were understated. “I think (the Lancet authors) have erred in their interpretation of the evidence,” Doshi said.

    The new study notes that the meta-analysis was funded by the Multiparty Group for Advice on Science (MUGAS), which obtained an unrestricted grant from Roche, stipulating the manufacturer could not be involved in the review process except to provide requested data and clarifications when needed. Results were not shared with the manufacturer until the analysis was completed, the paper said. It is also noted that one researcher, Dr. Richard Whitley, is a board member of Gilead Sciences, which has patents on the oseltamivir medication marketed by Roche. The manufacturer did not respond to requests for comment.

    However, Monto said the Cochrane group “uses that as a smokescreen.” If The Lancet believed total independence had not been demonstrated, it would not have published the results, he said.

    The CDC continues to stockpile the drug and recommends physicians use it quickly in symptomatic patients. It disagreed with the findings last year in the BMJ, and said that report did not tell the complete story.

    Widespread flu activity is being reported in 44 states with 9,926 flu-related hospitalizations since the start of flu season. Use of Tamiflu, Relenza and Rapivab are most effective within the first 48 hours of symptoms, said Dr. Tom Frieden, the agency's director, during a media briefing this month.

    “If those treated with Tamiflu don't have influenza, the benefit is going to be much higher,” he said. “More than half of the people with flu-like illness have confirmation that they have flu on detailed studies, but don't wait for confirmatory testing... it's not necessary to get the tests done before you treat the patient.”

    Follow Sabriya Rice on Twitter: @Sabriyarice

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    money arrows decrease down 2.png
    Changing employer market leaves digital health companies rethinking strategy
    Two pill bottles from Amazon Pharmacy
    Amazon rolls out generic drug subscription service
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Health IT Strategist (HITS) Newsletter: Sign up for the latest IT and medical technology news delivered 3 days a week (M, W, F).
     
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing